Oragenics (OGEN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OGEN Oragenics

Watchlist

0.2740
+0.0034+1.26%

Close Nov 22 16:00 ET

0.2982
+0.0242+8.83%

Post 19:44 ET

3.35MMarket Cap-39P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Seeking AlphaNov 18 00:09 ET
Oragenics | 10-Q: Q3 2024 Earnings Report
SECNov 13 14:43 ET · Announcements
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
GlobeNewswireOct 18 08:30 ET
Oragenics Shares Investor Presentation Online
TipRanksOct 16 10:57 ET
Express News | Oragenics Inc Says It May Offer Common Shares of up to $10 Mln
ReutersOct 15 06:07 ET
Express News | Oragenics Inc Says on October 11, Co Entered Into at-the-Market Sales Agreement With Dawson James Securities - SEC Filing
ReutersOct 15 06:05 ET

Comments

lfg might break . 5 right now

$Oragenics (OGEN.US)$

4

$Oragenics (OGEN.US)$

$Oragenics (OGEN.US)$

1

1

$Oragenics (OGEN.US)$
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Oragenics Inc. (NYSE American: OGEN) has successfully completed a key FDA-recognized study for its concussion drug, ONP-002. The study demonstrated that the intranasal delivery of ONP-002 effectively targets areas in the nose connected to the brain, increasing the likelihood of rapid brain treatment post-concussion. This achievement paves the way for Oragenics to proceed with Phase II human testin...

1

🚨 Pre Market Ticks 5:24am EST 10/8 🚨

$X4 Pharmaceuticals (XFOR.US)$ $The E.W. Scripps (SSP.US)$ $Leafly (LFLY.US)$ $Short FTSE China 25 Proshares (YXI.US)$ $Accolade (ACCD.US)$ $Oragenics (OGEN.US)$ $Virios Therapeutics (VIRI.US)$ $ProShares UltraShort FTSE China 50 (FXP.US)$ $Direxion Daily FTSE China Bear 3X Shares ETF (YANG.US)$ $Nuburu (BURU.US)$ $Ontrak (OTRK.US)$ $Nature's Miracle (NMHI.US)$

🚨 Pre Market Ticks 5:24am EST 10/8 🚨

5

Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall

No Data